Published in:

01-06-2008 | Original Article

Twenty-four-month α-galactosidase A replacement therapy in Fabry disease has only minimal effects on symptoms and cardiovascular parameters

Authors: J. W. Koskenvuo, J. J. Hartiala, P. Nuutila, R. Kalliokoski, J. S. Viikari, E. Engblom, M. Penttinen, J. Knuuti, I. Mononen, I. M. Kantola

Published in: Journal of Inherited Metabolic Disease | Issue 3/2008